EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade

Evan R Abt iD, Liang Wang, Grigor Varuzhanyan, Jack Freeland, Tian He, Guadalupe M Peña-Garcia, Lauryn Ruegg, Jami McLaughlin, Donghui Cheng, Nikolas G Balanis, Chia-Chun Chen, Yang Xu und 5 weitere

Proceedings of the National Academy of Sciences · 24.03.2026 · 123 (12)

DOI: 10.1073/pnas.2532814123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 20.03.2026. Verfasst von Evan R Abt und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095. Hauptthemen laut MEDLINE: E2F3 Transcription Factor, Pyrimidines, Synthetic Lethal Mutations, Retinoblastoma Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BLRD VA, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small cell carcinoma is a highly lethal cancer variant often found with neuroendocrine (NE) features, as exemplified by small cell lung cancer and small cell NE prostate cancer (SCPC). A genome-wide CRISPR dependency screen using SCPC models generated through human prostate cell transformation identifies a requirement for the transcription factor E2F3. E2F3 dependency is linked to RB inactivation, a near universal occurrence across small cell cancers. The requirement for E2F3 is shared by RB-deficient cells originating from the prostate, lung, and adnexa. In RB-deficient cancer cells, E2F3 inhibition restrains cell cycle progression, proliferation, and tumor growth in vivo. Inhibition of de novo pyrimidine synthesis limits E2F3 expression and suppresses small cell carcinoma proliferation in culture. Directly or indirectly targeting E2F3 to leverage a pan-cancer synthetic lethality resulting from RB inactivation represents a potential treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

E2F3 Transcription FactorPyrimidinesSynthetic Lethal MutationsRetinoblastoma ProteinCarcinoma, Small CellSmall Cell Lung CarcinomaHumansAnimalsMaleCell Line, TumorMiceCell ProliferationProstatic NeoplasmsLung Neoplasms

Stichwörter der Autor:innen

RB tumor suppressornucleotide metabolismsmall cell cancersynthetic lethality

Substanzen

E2F3 Transcription FactorPyrimidinesE2F3 protein, humanRetinoblastoma Proteinpyrimidine

Autor:innen und Institutionen

  • Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.
  • Jonsson Comprehensive Cancer Center, The David Geffen School of Medicine, University of California, Los Angeles, CA 90095.
  • Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095.
  • Department of Obstetrics and Gynecology, University of California, Los Angeles, CA 90095.
  • Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095.
  • Department of Pharmacology, Physiology and Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107.

ORCID-Profile: Evan R Abt, Caius G Radu, Thomas G Graeber, Owen N Witte

Förderung

  • BLRD VA
  • NCI NIH HHS

Zitieren

APA

Abt, E. R., Wang, L., Varuzhanyan, G., Freeland, J., He, T., Peña-Garcia, G. M., Ruegg, L., McLaughlin, J., Cheng, D., Balanis, N. G., Chen, C. C., Xu, Y., Xing, Y., Memarzadeh, S., Radu, C. G., Graeber, T. G., & Witte, O. N. (2026). Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade. Proceedings of the National Academy of Sciences, 123(12). https://doi.org/10.1073/pnas.2532814123

Vancouver

Abt ER, Wang L, Varuzhanyan G, Freeland J, He T, Peña-Garcia GM, et al. Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade. Proceedings of the National Academy of Sciences. 2026;123(12). doi:10.1073/pnas.2532814123

BibTeX
@article{Abt2026,
  author = {Abt, Evan R and Wang, Liang and Varuzhanyan, Grigor and Freeland, Jack and He, Tian and Peña-Garcia, Guadalupe M and Ruegg, Lauryn and McLaughlin, Jami and Cheng, Donghui and Balanis, Nikolas G and Chen, Chia-Chun and Xu, Yang and Xing, Yi and Memarzadeh, Sanaz and Radu, Caius G and Graeber, Thomas G and Witte, Owen N},
  title = {Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {12},
  doi = {10.1073/pnas.2532814123}
}
Kostenlos starten →